Medullary thyroid carcinoma is a progressive disease, which is rarely treated with radiotherapy or chemotherapy. Early total thyroidectomy, thyroxine replacement therapy, and normal food and maintenance can be done as normal. Regular ultrasound of the neck and chest examinations should be performed. In the past, it was thought that medullary thyroid cancer was resistant to radiation and radiotherapy was ineffective. In recent years, it is believed that postoperative positive margins, soft tissue invasion outside lymph nodes, and extensive mediastinal metastasis causing esophageal and tracheal invasion should be treated with external radiation palliative therapy (there are many radiotherapy devices, such as linear gas pedal and conformal intensity modulation technology, gamma knife, neutron knife, proton knife, heavy particle knife). Medullary thyroid carcinoma is a slow-onset tumor, and those with hepatopulmonary metastases can survive for several years without systemic therapy, so chemotherapy has no role in the early treatment of medullary thyroid carcinoma. Chemotherapy has only been used as palliative treatment for rapidly progressive medullary thyroid cancer with distant metastases in several studies. In 1985, Skimooka et al. reported that the partial efficiency of adriamycin alone did not exceed 15%-20%, and the combination with cisplatin or streptomycin did not improve the efficacy. In recent years, with the progress of immunology, the use of anti-CEA monoclonal antibodies labeled with different nucleophiles has been effective in the treatment of advanced medullary thyroid cancer. However, radioimmunotherapy is still immature and needs to be further developed.186 Re -DMSA has the potential to act as a radiation-directed therapy for MTC, but its use in the clinic needs to be further improved and evaluated. About iodine 125 implantation therapy Iodine 125 implantation therapy is a new technique in oncology treatment and can be an option if necessary.